Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
Ad icon
V2ray VPN for Tunneling
hu KANNA
Updated:
Oct 22, 2026
FREE SEO Check & Google Maps Check for Sri Lankan Businesses | Web Design, Website Price Rs 14,900 |
LankaSolve
Updated:
Oct 20, 2026
ඕනම රටකට සෙට් වෙන CV එකක්
ErMurazor
Updated:
Oct 17, 2026
Hambantota
7 Acres Beachfront Land For Sell DownSouth , PerPerch Price 420 000
1024 Digital
Updated:
Oct 14, 2026
Baseus PI LITE INDOOR CAMERA
ErMurazor
Updated:
Oct 12, 2026
Electronics
Vehicles
Property
Search
Reply to thread
Forums
General
ElaKiri Talk!
Chikungunya Vaccines
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 30786105" data-attributes="member: 562115"><p>Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), an RNA virus belonging to the <em>Alphavirus</em> genus within the family <em>Togaviridae</em>. Primarily transmitted by bites from infected <em>Aedes</em> mosquitoes (<em>Aedes aegypti</em> and <em>Aedes albopictus</em>), the disease is characterized by the sudden onset of fever, joint pain (arthralgia), and rashes, with approximately 50% of detected acute cases developing chronic joint pain that may persist for several months. CHIKV-associated mortality is rare (~1 death per 1,000 cases)</p><p></p><p>The recently licensed IXCHIQ vaccine (VLA1553, Valneva Austria GmbH), has received both the FDA & EMA approval for individuals 18 years of age and older who are at increased risk of exposure to CHIKV. The EMA approval is for 18 - 64 only. They recommend that Ixchiq must not be given to people aged 65 years and older or people who are immunodeficient or immunosuppressed (have a weakened immune system) due to a disease or treatment.</p><p></p><p>The FDA and CDC are recommending (7 May 2025) a pause in the use of Ixchiq (Chikungunya Vaccine, Live) in individuals 60 years of age and older while the Agencies investigate postmarketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine.</p><p><strong>As of May 7, 2025, 17 serious adverse events, including two that resulted in death, have been reported in individuals 62 through 89 years of age who received Ixchiq during postmarketing use globally. </strong></p><p><strong>It's a live attenuated vaccine using the strain CHIKV LR2006-OPY1.</strong></p><p><strong></strong></p><p><strong>Also there's VIMKUNYA™ </strong>by Bavarian Nordic. It's a Recombinant vaccine, the first virus-like particle (VLP) single-dose chikungunya vaccine and the first chikungunya vaccine for individuals over the age of 12. It's EMA and FDA approved for over 12 year olds.</p></blockquote><p></p>
[QUOTE="imhotep, post: 30786105, member: 562115"] Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), an RNA virus belonging to the [I]Alphavirus[/I] genus within the family [I]Togaviridae[/I]. Primarily transmitted by bites from infected [I]Aedes[/I] mosquitoes ([I]Aedes aegypti[/I] and [I]Aedes albopictus[/I]), the disease is characterized by the sudden onset of fever, joint pain (arthralgia), and rashes, with approximately 50% of detected acute cases developing chronic joint pain that may persist for several months. CHIKV-associated mortality is rare (~1 death per 1,000 cases) The recently licensed IXCHIQ vaccine (VLA1553, Valneva Austria GmbH), has received both the FDA & EMA approval for individuals 18 years of age and older who are at increased risk of exposure to CHIKV. The EMA approval is for 18 - 64 only. They recommend that Ixchiq must not be given to people aged 65 years and older or people who are immunodeficient or immunosuppressed (have a weakened immune system) due to a disease or treatment. The FDA and CDC are recommending (7 May 2025) a pause in the use of Ixchiq (Chikungunya Vaccine, Live) in individuals 60 years of age and older while the Agencies investigate postmarketing reports of serious adverse events, including neurologic and cardiac events, in individuals who have received the vaccine. [B]As of May 7, 2025, 17 serious adverse events, including two that resulted in death, have been reported in individuals 62 through 89 years of age who received Ixchiq during postmarketing use globally. It's a live attenuated vaccine using the strain CHIKV LR2006-OPY1. Also there's VIMKUNYA™ [/B]by Bavarian Nordic. It's a Recombinant vaccine, the first virus-like particle (VLP) single-dose chikungunya vaccine and the first chikungunya vaccine for individuals over the age of 12. It's EMA and FDA approved for over 12 year olds. [/QUOTE]
Insert quotes…
Verification
Asuwa dahayen wadi kalama keeyada?
Post reply
Top
Bottom